GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PDS Biotechnology
PDS Biotechnology is a biotech company developing immunotherapies for the treatment of cancer and infectious diseases. Its stock price is driven by news of clinical trials. The chart reflects investor confidence in the potential of its Versamune platform.
Share prices of companies in the market segment - Oncology immuno-therapy
PDS Biotechnology develops immunotherapeutic drugs based on its Versamune platform for the treatment of various types of cancer. We've categorized it as "Immuno-Oncology," and the chart below shows how investors value companies working to activate the immune system to fight cancer.
Broad Market Index - GURU.Markets
PDS Biotechnology develops immunotherapeutic drugs based on its Versamune platform for the treatment of various types of cancer. It is a component of the GURU.Markets index. The chart below shows the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
PDSB - Daily change in the company's share price PDS Biotechnology
PDS Biotechnology Corp.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its immunotherapy drugs.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
PDS Biotechnology Corporation is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with PDSB's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
PDS Biotechnology is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PDS Biotechnology
PDS Biotechnology's year-over-year performance is the story of its immunotherapeutic vaccine platform. Its 12-month market cap is entirely dependent on clinical trial data. Success in its approach, which activates T cells to fight cancer, could be a breakthrough, particularly in the treatment of HPV-associated tumors.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
PDS Biotechnology Corporation is a clinical-stage biotech company developing immunotherapy for cancer treatment. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
PDS Biotechnology is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its immunotherapy platform. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PDS Biotechnology
PDS Biotechnology is an immuno-oncology company. Its monthly performance is driven by progress in clinical trials of its Versamune platform. Positive data from its programs, presented at conferences, and partnership news are the main drivers of its valuation.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immuno-oncology vaccines are an innovative approach to cancer treatment. The performance of this biotech sector, as seen in the chart, reflects investor confidence in these new platforms. Companies like PDS Biotechnology are conducting clinical trials in this cutting-edge field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
PDS Biotechnology, a biopharmaceutical company focused on immuno-oncology, thrives in a world of clinical data. Its shares rise and fall on trial news, defying overall market trends. This chart demonstrates this independence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PDS Biotechnology
For PDS Biotechnology, an oncology company, the weekly performance has been extremely volatile. News about the progress of clinical trials of its immunotherapy platform, especially in combination with other drugs, has caused sharp and significant price movements.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
PDS Biotechnology and the entire oncology biotech sector are riding the same news and sentiment. Breakthroughs in immunotherapy or changes in FDA policy could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
PDS Biotechnology and the entire oncology biotech sector are riding the same news and sentiment. Breakthroughs in immunotherapy or changes in FDA policy could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Market capitalization of the company, segment and market as a whole
PDSB - Market capitalization of the company PDS Biotechnology
PDS Biotechnology's market capitalization is the financial valuation of a biotech company with the Versamune platform for activating T-cells against cancer. The chart reflects investor expectations for its leading developments in immuno-oncology. Its speculative dynamics tell the story of how the market reacts to clinical trial data and partnerships.
PDSB - Share of the company's market capitalization PDS Biotechnology within the market segment - Oncology immuno-therapy
PDS Biotechnology develops immunotherapeutic drugs based on its Versamune platform for the treatment of cancer and infectious diseases. Its market share reflects the potential of its technology to stimulate a potent T-cell response. The chart below is an indicator of the market's confidence in its scientific approach.
Market capitalization of the market segment - Oncology immuno-therapy
PDS Biotechnology is developing immunotherapy based on its Versamune platform. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the search for new ways to activate the immune system. PDS is betting on its unique technology to fight cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
The cancer immunotherapy shown in the graph uses viruses to deliver drugs. PDS Biotechnology is developing a lipid particle-based platform to activate a potent T-cell response. Its capitalization is a risky bet on its technology and the success of its clinical programs.
Book value capitalization of the company, segment and market as a whole
PDSB - Book value capitalization of the company PDS Biotechnology
PDS Biotech's book value is capital for the development of next-generation immunotherapies. Currently in the R&D stage, the company is using its financial assets to develop the Versamune platform, which "activates" T cells to combat HPV-induced cancer and other diseases.
PDSB - Share of the company's book capitalization PDS Biotechnology within the market segment - Oncology immuno-therapy
PDS Biotechnology, a biopharmaceutical company, develops next-generation immunotherapies. Its share of the sector's assets consists of R&D laboratories. Its value lies in its unique Versamune platform, which activates T cells to fight cancer.
Market segment balance sheet capitalization - Oncology immuno-therapy
PDS Biotechnology is a clinical-stage immuno-oncology company, making its model asset-light. The company's value lies in its scientific platform and clinical trial data. Compared to the biotech sector as a whole, its low capital intensity is typical of innovative R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
PDS Biotech's assets are not drugs, but rather a unique immunotherapy platform, Versamune, which "trains" T cells to mount a powerful attack on cancer and infectious diseases. The company's balance sheet reflects the value of this technology. The chart shows how much capital is invested in this new method of activating the immune system.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PDS Biotechnology
PDS Biotechnology is an immuno-oncology company. Its market value is derived from its unique T-cell activation platform. Investors are betting on its potential to create a new generation of cancer vaccines, creating a huge gap with its book value.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
PDS Biotechnology is developing immunotherapy for cancer treatment. Its value lies in its proprietary platform, which it claims enhances the immune response. This chart shows how the market valuation based on the potential of this technology is many times greater than the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
PDS Biotechnology is an oncology company developing immunotherapy. Its value is determined by the potential of this innovative technology. This chart shows how biotech market valuations are based on future scientific breakthroughs rather than current tangible assets, which contrasts sharply with the market average.
Debts of the company, segment and market as a whole
PDSB - Company debts PDS Biotechnology
PDS Biotechnology develops immunotherapeutic drugs for the treatment of cancer. Its unique technology requires significant resources for clinical trials. Debt capital is the company's way of financing this long and risky journey to create a new generation of cancer drugs.
Market segment debts - Oncology immuno-therapy
PDS Biotechnology is a clinical-stage biopharmaceutical company developing immunotherapy for cancer. Funding is key to advancing its platform through expensive trials. This chart shows whether the company is following the standard biotech equity model to fund its innovative research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PDS Biotechnology
PDS Biotechnology, an immuno-oncology company, develops drugs to stimulate the immune response against cancer. This chart shows how dependent it is on debt. Like many biotech companies, its future depends on the success of clinical trials. High debt means the cost of failure could be fatal for the company.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
PDS Biotechnology is developing a next-generation immunotherapy for cancer treatment based on its Versamune® platform, which activates T cells. This chart compares the debt raised for this cutting-edge research with the total market capitalization of the entire immuno-oncology sector. It illustrates the financial implications of this innovative technology.
Debt to book value of all companies in the market
PDS Biotechnology is developing immunotherapeutic drugs based on its innovative platform. Funding clinical trials is the company's primary goal at this stage. The chart demonstrates how it manages its debt to achieve this goal. A comparison with the biotech sector allows for an assessment of its financial risks and potential prior to commercialization.
P/E of the company, segment and market as a whole
P/E - PDS Biotechnology
For PDS Biotechnology, a company developing cancer immunotherapy, this chart represents the valuation of its unique technology. The stock price relative to future earnings reflects investors' belief that its platform can significantly improve treatment effectiveness. The price movement is a direct response to clinical trial data.
P/E of the market segment - Oncology immuno-therapy
This chart reflects the average valuation for the speculative immuno-oncology sector—the benchmark for PDS Biotechnology. The high valuation of the entire industry reflects confidence in this approach to cancer treatment. Comparison with this metric helps understand whether investors view the PDS platform as particularly promising.
P/E of the market as a whole
PDS Biotechnology develops immunotherapeutic drugs based on its Versamune platform, which aims to stimulate a potent T-cell response against cancer and infectious diseases. This chart shows the market's risk appetite, allowing investors to understand how this technology platform is perceived and how clinical trial data influences the company's valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PDS Biotechnology
PDS Biotechnology is developing an immunotherapy based on its Versamune platform for cancer treatment. This chart reflects analyst expectations for the company's clinical trials. It shows whether they believe its technology will effectively activate T cells to fight tumors and become a successful commercial product.
%20P%2FE%20PDS%20Biotechnology&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PDS-Biotechnology&v=1772513566949 "Chart of the company's future (projected) P/E PDS Biotechnology")
Future (projected) P/E of the market segment - Oncology immuno-therapy
PDS Biotechnology develops immunotherapeutic drugs based on its Versamune platform for cancer treatment. This chart compares its future profitability expectations with those of the immuno-oncology sector. It demonstrates the level of investor confidence in its technology, which is designed to stimulate a potent and targeted T-cell response against tumors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772513566966 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
PDS Biotechnology is developing a cancer immunotherapy based on its Versamune platform. This chart shows the overall risk appetite. PDSB's success depends on the results of clinical trials. A positive market environment helps with funding but cannot replace scientific data, which is the primary driver of value.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513566995 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PDS Biotechnology
PDS Biotechnology is a clinical-stage immuno-oncology company developing a T-cell activation platform to fight cancer. This chart shows the financial trajectory of this biotech innovation. Current results reflect investments in clinical trials aimed at creating a new generation of cancer vaccines.
Profit of companies in the market segment - Oncology immuno-therapy
PDS Biotechnology develops immunotherapeutics based on its Versamune platform, which stimulates a potent and targeted T-cell response to fight cancer. This chart illustrates the financial climate in the immuno-oncology sector, reflecting the high investor interest in innovative platforms capable of boosting immune response against cancer.
Overall market profit
PDS Biotechnology is an immuno-oncology company developing cancer vaccines. Its success depends on the results of clinical trials. The need for cancer treatments is not dependent on the state of the economy. However, favorable stock market conditions, which often coincide with rising corporate profits, facilitate the raising of capital for research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PDS Biotechnology
PDS Biotechnology is developing immunotherapy based on its unique Infectimune™ platform, which is designed to activate T cells to fight cancer. This graph represents a long-term model reflecting analysts' confidence in the scientific and commercial potential of this innovative technology.
%20profit%20of%20the%20company%20PDS%20Biotechnology&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PDS-Biotechnology&v=1772513567044 "Graph of future (projected) profit of the company PDS Biotechnology")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
PDS Biotechnology is developing a new generation of immunotherapeutic drugs for cancer treatment based on its proprietary Infectimune platform. This chart shows forecasts for the biotech sector. PDS's future profitability depends on the success of its technology in activating a potent and targeted T-cell response against tumors in clinical trials.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772513567084 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
PDS Biotechnology develops immunotherapeutic drugs for cancer treatment. Like any biotech company, it requires a constant influx of capital to support its research. This graph, showing profit expectations, is an indicator of the overall investment climate and investor willingness to fund risky but promising scientific research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513567104 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PDS Biotechnology
PDS Biotechnology develops immunotherapeutic drugs based on its Versamune platform for cancer treatment. This chart reflects investor confidence in the company's scientific potential. The valuation is based not on current sales, but on expectations from clinical trials and the platform's ability to enhance immune responses.
P/S market segment - Oncology immuno-therapy
PDS Biotechnology is developing the Versamune platform, which enables the creation of immunotherapeutic drugs for the treatment of cancer and infectious diseases by activating a powerful T-cell response. This chart reflects the average biotech valuation, helping to understand how highly the market values the potential of this innovative and versatile technology platform.
P/S of the market as a whole
PDS Biotechnology is developing a platform for creating next-generation immunotherapeutic drugs for cancer treatment. Its goal is to stimulate a powerful and targeted immune response. This graph of average market revenue estimates clearly demonstrates that the company's valuation is based not on current sales, but on the potential of its scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PDS Biotechnology
PDS Biotechnology is developing immunotherapeutic drugs based on its Versamune platform for cancer treatment. This chart reflects investor confidence in the potential of this technology to stimulate immune responses. The valuation is based on expected future revenues, which depend on successful clinical trial results.
%20P%2FS%20PDS%20Biotechnology&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PDS-Biotechnology&v=1772513567172 "The graph of the company's future (projected) P/S PDS Biotechnology")
Future (projected) P/S of the market segment - Oncology immuno-therapy
PDS Biotechnology develops immunotherapy for the treatment of cancer. This chart compares the company's future revenue expectations with its sector. It reflects investor confidence in its unique technology platform and the potential of its drug candidates, particularly in combination with other treatments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772513567225 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
PDS Biotechnology is a clinical-stage immuno-oncology company developing a platform for T-cell activation to destroy cancer tumors. This chart shows overall revenue expectations, and PDS Biotech is working on developing a new generation of cancer vaccines. The success of its platform could revolutionize treatment approaches.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513567260 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PDS Biotechnology
PDS Biotechnology is a clinical-stage biopharmaceutical company developing cancer immunotherapy. Its revenue, shown in this chart, is generated not from sales but from grants, licensing agreements, and collaboration fees that fund its research and clinical trials.
Sales of companies in the market segment - Oncology immuno-therapy
PDS Biotechnology is developing an immunotherapy platform for cancer and infectious diseases designed to activate a powerful and targeted immune response. This graph reflects the enormous potential of immunology, where innovative platforms like PDS's can form the basis for the creation of next-generation vaccines and drugs.
Overall market sales
PDS Biotechnology Corporation develops immunotherapeutic drugs for the treatment of cancer. Its activities require significant investment in clinical research. The growth in total economic revenue, reflected in this chart, creates a favorable investment climate. This facilitates raising the capital needed to advance the company's innovative vaccines and therapeutics.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PDS Biotechnology
PDS Biotechnology is developing a platform for the creation of immunotherapeutic drugs that activate a powerful and targeted T-cell response to combat cancer and infectious diseases. This schedule reflects analysts' expectations for the success of clinical trials of this innovative technology.
%20sales%20of%20the%20company%20PDS%20Biotechnology&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PDS-Biotechnology&v=1772513567410 "Schedule of future (projected) sales of the company PDS Biotechnology")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
PDS Biotechnology develops immunotherapeutics based on its Versamune platform, which stimulates potent T-cell responses against cancer and infectious diseases. This chart shows forecasts for the immuno-oncology sector, illustrating how new platforms can enhance the effectiveness of vaccines and other immunotherapies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772513567443 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
PDS Biotechnology, an immuno-oncology company, sees this chart as an indicator of the investment climate in biotech. The strong economic forecasts reflected here are stimulating capital flows into innovative R&D projects and creating a favorable environment for the development of their unique platform for activating the immune response against cancer.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513567477 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PDS Biotechnology
PDS Biotechnology is a clinical-stage biotech company developing immunotherapies for cancer and infectious diseases. This chart reflects the company's current phase: a period of intensive investment in clinical trials. It shows how capital is being directed toward validating the efficacy of their innovative Versamune platform.
Market segment marginality - Oncology immuno-therapy
PDS Biotechnology develops immunotherapies against cancer and infectious diseases based on its Versamune platform. The strength of this type of biotech lies in its ability to quickly and affordably prove the efficacy of its technology in the clinic. The chart below illustrates the company's operating model compared to its competitors in immuno-oncology.
Market marginality as a whole
PDS Biotechnology is developing cancer immunotherapy based on its proprietary Versamune platform. This graph shows average profitability, while PDS Bio is working on T-cell activation to fight tumors. Their financial success depends on clinical trial results and partnerships.
Employees in the company, segment and market as a whole
Number of employees in the company PDS Biotechnology
PDS Biotechnology is developing next-generation immunotherapies for cancer treatment. This graph shows its team of scientists and clinicians. The growth in staff reflects the progress of its core technology, Versamune, and the advancement of its drug candidates through clinical trials.
Share of the company's employees PDS Biotechnology within the market segment - Oncology immuno-therapy
PDS Biotechnology is developing a new generation of cancer immunotherapies based on its Versamune platform. This chart shows the proportion of all scientists working in this cutting-edge field that PDS employs. This reflects its scientific potential and the uniqueness of its approach to T-cell activation to fight tumors.
Number of employees in the market segment - Oncology immuno-therapy
PDS Biotechnology is developing a platform for activating the immune system to fight cancer. Its main asset is its team of scientists. This chart shows how the company is investing in its research. Staff growth directly correlates with progress in clinical trials and the expansion of its immunotherapy platform.
Number of employees in the market as a whole
PDS Biotechnology is developing immunotherapy based on its Versamune platform. In the world of biotech, data is king. This graph reflects overall workload, but for PDS, publishing positive clinical trial results could be a catalyst for attracting investment and hiring dozens of new scientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PDS Biotechnology (PDSB)
PDS Biotechnology is an immuno-oncology R&D company. Its value is determined by the prospects of its scientific platform. This chart shows that its market capitalization is driven by a small team of brilliant scientists. The sky-high per-employee value reflects the market's valuation of its intellectual capital.
%20of%20the%20company%20PDS%20Biotechnology%20(PDSB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PDS-Biotechnology-PDSB&v=1772513567601 "Chart of market capitalization per employee (in thousands of dollars) of the company PDS Biotechnology (PDSB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
PDS Biotechnology develops immunotherapeutic drugs based on its Versamune platform. The company's valuation is dependent on the clinical success of its developments. This metric demonstrates how highly investors value the potential of this unique technology for fighting cancer and infectious diseases, based on its scientific team.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772513567616 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
PDS Biotechnology is developing cancer immunotherapy based on its Versamune platform. It's a science-intensive biotech company. This chart demonstrates the company's high market valuation per employee, as investors see great potential in this technology capable of activating a powerful and targeted immune response against tumors.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513567620 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PDS Biotechnology (PDSB)
PDS Biotechnology is a biopharmaceutical company developing immuno-oncology drugs based on its platform (Versamune). It's an R&D business. This chart reflects the R&D capital burn per scientist. This represents an investment in scientific development that could generate significant profits in the future.
%20Chart%20PDS%20Biotechnology%20(PDSB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PDS-Biotechnology-PDSB&v=1772513567635 "Company Profit Per Employee (in thousands of dollars) Chart PDS Biotechnology (PDSB)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
PDS Biotechnology (PDSB) is a biopharmaceutical company specializing in immuno-oncology. They are developing the Versamune platform for T-cell activation. Currently in the clinical stage, the company is focused on R&D. This chart shows how effectively the team is using capital to advance their technology platform through clinical trials.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772513567651 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
PDS Biotechnology is a biotech company developing immunotherapies for cancer and infectious diseases. The company is in the clinical stage. This graph shows negative profit per employee, which is typical for the R&D sector. Each employee is a scientist or physician whose work is an investment in future drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513567689 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PDS Biotechnology (PDSB)
PDS Biotechnology is a biopharmaceutical company developing immunotherapy for cancer treatment. At the clinical trial stage, this graph reflects future potential. Significant revenue per employee will only emerge after drug approval or a major partnership, demonstrating the value of their scientific platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PDS-Biotechnology-PDSB&v=1772513567693 "Sales chart per company employee PDS Biotechnology (PDSB)")
Sales per employee in the market segment - Oncology immuno-therapy
PDS Biotechnology is a biotech company developing immunotherapies for cancer and infectious diseases based on its Versamune platform. This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required in this industry to successfully commercialize an R&D platform.
Sales per employee for the market as a whole
PDS Biotechnology (PDSB) is a biotechnology company developing immunotherapies for cancer and infectious diseases based on its Versamune® platform. It is an R&D company. This chart shows the current (minimum) partnership revenue per scientist while the drugs are in clinical development.
Short shares by company, segment and market as a whole
Shares shorted by company PDS Biotechnology (PDSB)
PDS Biotechnology is developing cancer immunotherapy based on its Versamune platform. The company is targeting HPV-related cancers. The chart shows the number of investors skeptical of this technology. They are betting that the platform will fail to prove effective in late-stage trials or will lose out to the competition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PDS-Biotechnology-PDSB&v=1772513567820 "Short Shares Chart for the Company PDS Biotechnology (PDSB)")
Shares shorted by market segment - Oncology immuno-therapy
PDS Biotechnology is developing cancer immunotherapies (vaccines) based on its Versamune platform. This indicator measures overall skepticism in the pharmaceutical industry. When it is high, it indicates that investors generally lack confidence in the success of clinical trials or anticipate funding challenges across the industry.
Shares shorted by the overall market
PDS Biotechnology is developing immunotherapy to activate T-cells against cancer. This is a highly competitive field, requiring massive investments in R&D. This chart measures the level of market fear. When pessimism rises, investors are reluctant to fund "research projects." They sell off PDSB shares, fearing the company won't make it to the finish line before running out of money.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PDS Biotechnology (PDSB)
PDS Biotechnology is developing an immunotherapy based on its Versamune® platform for cancer treatment. Like many biotechs, the company's shares are driven by trial news. This oscillator measures the market's "temperature," showing when the stock is "overheated" (above 70) in anticipation of a breakout or "oversold" (below 30) due to a lack of news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PDS-Biotechnology-PDSB&v=1772513567931 "RSI 14 indicator chart for the company's stock PDS Biotechnology (PDSB)")
RSI 14 Market Segment - Oncology immuno-therapy
PDS Biotech (PDSB) is a "biotech" and an immune "coach." Their *platform* (Versamune) *boosts* T-cell responses for *vaccines* against *cancer* and *infections*. The "Oncology immuno-therapy" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is PDSB's growth due to their R&D or is *the entire* biotech "overheated"?
RSI 14 for the overall market
PDS Biotechnology (PDSB) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PDSB (PDS Biotechnology)
PDS Biotechnology (PDSB) is an immuno-oncology company developing the Versamune platform for "training" T cells to attack cancer, specifically HPV-associated tumors. This chart shows the average price target, reflecting analysts' confidence in this technology and its clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PDSB-PDS-Biotechnology&v=1772513568065 "A chart showing analyst consensus forecasts for the expected stock price. PDSB (PDS Biotechnology)")
The difference between the consensus estimate and the actual stock price PDSB (PDS Biotechnology)
PDS Biotechnology (PDSB) is an oncology company developing immunotherapy (based on IL-12) for the treatment of HPV-associated cancer. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PDSB-PDS-Biotechnology&v=1772513568252 "A chart showing the difference between the consensus forecast and the actual stock price. PDSB (PDS Biotechnology)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
PDS Biotechnology is a biotech company developing immunotherapies (based on its Versamune platform) for the treatment of cancer (HPV-associated) and infectious diseases. This chart shows analysts' overall expectations for the immunotherapy sector, reflecting their confidence in the success of this R&D platform.
Analysts' consensus forecast for the overall market share price
PDS Biotechnology is a clinical-stage company specializing in immuno-oncology. It's an R&D company that's burning cash. This chart, reflecting the market's overall risk appetite, is vital. When optimism is high, investors fund speculative research. When pessimism ("risk-off") takes over, funding for biotechs like PDSB disappears.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PDS Biotechnology
PDS Biotechnology is a biotech company focused on immuno-oncology. Their flagship platform (Versamune) is designed to train and activate T cells to fight cancer (such as HPV-related cancer) and infectious diseases. This chart is a clear indicator of their R&D confidence. Its dynamics reflect the market's speculative assessment of their clinical data, trial progress, and the potential of their technology platform.
AKIMA Market Segment Index - Oncology immuno-therapy
PDS Biotechnology (PDSB) is an immuno-oncology company developing cancer vaccines based on its Versamune platform. This technology trains T cells to attack tumors. The chart shows the average index for the segment, helping investors assess how market expectations for PDSB's platform compare to the average risk in the immunotherapy sector.
The AKIM Index for the overall market
PDS Biotechnology is an immuno-oncology company developing cancer vaccines (Versamune) and cytokines. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to the overall economic trends affecting the biotech sector.
